source
- AI’s role in medicine isn’t monolithic, says industry leader, urging nuanced adoptionPriya Abani, CEO of health‑tech firm AliveCor, argues that asking whether AI is good for medicine is a question with an obvious answer: it is. She says the debate has become redundant and that the…
- Cardiac biotech Braveheart raises $382.5M in IPO, launches on Nasdaq as BRVEBraveheart Bio, a cardiac drug developer, priced its initial public offering on Wednesday and secured $382.5 million in proceeds. The company sold about 21.2 million shares at $18 each, exceeding t…